


(c) Effects stratified by Blinding status

Number of trials (patients) that contribute to meta-analysis:

Risk of Bias	Number of trials	Number of patients	Pooled MD	LCI	UCI	p-value	I-squared
All	9	1170	-0.844	-1.816	0.128	0.089	0.000
Placebo-controlled	2	200	-0.152	-2.723	2.419	0.908	0.000
Open-label	7	970	-0.960	-2.010	0.090	0.073	0.000

Effects of anti-IL-6 therapy, stratified by Blinding status



Differences in mean differences (DMD) comparing the effect of Anti-IL6 between Blinding status subgroups:

Comparison of effects by Blinding status	DMD	LCI	UCI	p-value
Open-label vs Placebo-controlled	0.446	0.016	12.716	0.586

A $DMD < 0$ suggests that the estimated effect (of anti-IL6 versus usual care/placebo) is more beneficial for the first group than the second.

Test of Blinding effect: $F(1, 7) = 0.33$ on 1 d.f., $p = 0.586$

IL-6 PMA results for Duration of IMV ----- Page number: 12